<DOC>
	<DOCNO>NCT01320527</DOCNO>
	<brief_summary>Based prior publish pilot study , investigator initiate large , multi-site placebo-controlled clinical trial Alzheimer 's disease ( AD ) patient individual diagnose Mild Cognitive Impairment ( MCI ) , hop ( 1 ) confirming ( deny ) promise clinical finding , ( 2 ) determine whether formulation delay MCI `` conversion '' AD .</brief_summary>
	<brief_title>A Clinical Trial Vitamin/Nutriceutical Formulation Alzheimer 's Disease</brief_title>
	<detailed_description>Preclinical study mouse model age-related neurodegeneration lead u develop Nutriceutical Formulation ( `` NF '' ) consist 6 over-the-counter vitamin nutriceuticals , buffer multiple facet Alzheimer 's disease ( AD ) , include ( 1 ) reduce presenilin expression , gamma-secretase activity , Abeta generation tau phosphorylation , ( 2 ) buffer homocysteine Abeta-induced oxidative damage , ( 3 ) reduce aggression , ( 4 ) increase acetylcholine production improving/maintaining cognitive performance . A 1-year , open-label trial NF mild moderate AD patient demonstrate improvement cognitive performance ( Dementia Rating Scale , Clock-drawing ) within 3-6 month . Caregivers report maintenance daily performance improve mood ( ADCS-Activities Daily Living NeuroPsychiatric Inventory ) . A placebo-controlled study moderate late-stage AD indicate delay cognitive decline maintenance daily activity . No adverse event report . A multi-site trial &gt; 90 individual age 45-73 without dementia indicate NF statistically improve executive function ( Trails B-A ) vs. placebo within 3 month , increase 6 month . The placebo group demonstrate identical improvement 3-month open-label extension . Following NF withdrawal , participant return baseline ; statistically-significant improvement restore NF individual resume . We initiate large , multi-site placebo-controlled clinical trial AD patient individual diagnose Mild Cognitive Impairment ( MCI ) , hop ( 1 ) confirming ( deny ) promise clinical finding , ( 2 ) determine whether formulation delay MCI `` conversion '' AD .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Cognition Disorders</mesh_term>
	<mesh_term>Mild Cognitive Impairment</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin A</mesh_term>
	<mesh_term>Retinol palmitate</mesh_term>
	<criteria>Clinical diagnosis Alzheimer 's disease Mild Cognitive Impairment must able swallow pill know suspect bipolar disorder</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>dietary supplement</keyword>
	<keyword>cognition</keyword>
	<keyword>mood</keyword>
	<keyword>Alzheimer 's disease</keyword>
	<keyword>memory loss</keyword>
</DOC>